Google_______________

New Data Suggest that Patients with Chronic Liver Disease are at Increased Risk for Heart Disease

By Liz Highleyman

Past studies have produced conflicting data regarding the prevalence of cardiovascular disease risk factors -- including insulin resistance and elevated blood lipids -- in people with hepatitis C.

As reported in the June 2007 Journal of Hepatology, Italian researchers conducted a study to analyze carotid intima-media thickness (IMT) in patients with 3 forms of chronic liver disease:

Chronic hepatitis B virus (HBV) infection;

Chronic hepatitis C virus (HCV) infection;

Non-alcoholic steatohepatitis (NASH).

Increased carotid IMT -- a measure of the health of the carotid arteries in the neck -- is an indicator of early atherosclerosis, or "hardening of the arteries."

The investigators studied 60 consecutive patients with biopsy-proven NASH, 60 with HCV, 35 with HBV, and 60 healthy control subjects of comparable age and sex. Common carotid IMT was measured using ultrasonography.

Results

Carotid IMT measurements were markedly different among the groups:

- lowest in healthy controls (0.84);
- intermediate in patients with HBV or HCV (0.97 and 1.09, respectively);
- highest in those with NASH (1.23) (P < 0.001).

These differences among the groups were minimally affected by adjustment for age, sex, body mass index, smoking, low-density lipoprotein (LDL, or "bad") cholesterol levels, insulin resistance, and components of metabolic syndrome (as defined by the Adult Treatment Panel III).

In a logistic regression analysis, NASH, HBV, and HCV all predicted increased carotid IMT, independent of potential confounders.

Conclusion

In conclusion, the authors wrote, "These data suggest that NASH, HCV, and HBV are strongly associated with early atherosclerosis independent of classical risk factors, insulin resistance, and metabolic syndrome components."

06/29/07

Reference
G Targher, L Bertolini, R Padovani, and others. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. Journal of Hepatology 46(6): 1126-1132. June 2007.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved
Combination
Therapies
for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Index of All
Hepatitis C Articles
by Topic ( A to Z)